Sign In
Buy SMID
$29.95
-1.26 (-4.04%)
At Close: Jun 03, 2026
Smith-Midland Posts Y/Y Earnings Rise in 2024 on Strong Product Demand
12:30pm, Thursday, 29'th May 2025
SMID reports record 2024 results, with revenues rising 32% y/y, driven by strong product demand and a strategic shift toward higher-margin barrier rentals.
Smith-Midland Reports Fourth Quarter and Year End 2024 Financial Results
05:45pm, Tuesday, 27'th May 2025
Highest Annual Revenue and Net Income in Company History MIDLAND, VA / ACCESS Newswire / May 27, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and
Oceaneering to Participate at Citi's 2025 Spotlight on SMID Energy Day
05:01pm, Wednesday, 14'th May 2025
HOUSTON--(BUSINESS WIRE)--Oceaneering to Participate at Citi's 2025 Spotlight on SMID Energy Day.
Smith-Midland Producing $2M in SlenderWall for Newport News Shipyard Project
10:50am, Thursday, 01'st May 2025
MIDLAND, VA / ACCESS Newswire / May 1, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, will begin
Dominic Hunter Joins Smith-Midland as Chief Financial Officer
04:15pm, Wednesday, 23'rd Apr 2025
MIDLAND, VA / ACCESS Newswire / April 23, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, announc
Smith-Midland Receives NASDAQ Deficiency Notice Regarding Delayed Form 10-K Filing
10:20am, Wednesday, 23'rd Apr 2025
MIDLAND, VA / ACCESS Newswire / April 23, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, today a
Hotchkis & Wiley Launches SMID-Cap Diversified Value ETF (HWSM)
08:30am, Tuesday, 08'th Apr 2025
LOS ANGELES--(BUSINESS WIRE)--Global investment manager Hotchkis & Wiley launches first ETF, the Hotchkis & Wiley SMID-Cap Diversified Value Fund (HWSM).
Smith-Midland Awarded $5M SlenderWall Contract for FBI Project
08:30am, Thursday, 03'rd Apr 2025
Smith-Midland to Produce SlenderWall for FBI Dorm Re-Cladding Project in Virginia MIDLAND, VA / ACCESS Newswire / April 3, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, hig
Smith-Midland Announces Delayed Filing of 2024 Form 10-K and Announces Preliminary Full-Year Revenue
04:15pm, Monday, 31'st Mar 2025
MIDLAND, VA / ACCESS Newswire / March 31, 2025 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary and patented precast concrete products and
Smith-Midland Announces Delayed Filing of 2024 Form 10-K and Announces Preliminary Full-Year Revenue
04:15pm, Monday, 31'st Mar 2025
MIDLAND, VA / ACCESS Newswire / March 31, 2025 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary and patented precast concrete products and
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
04:15pm, Monday, 03'rd Feb 2025
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
09:00am, Friday, 31'st Jan 2025
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focuse
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Thursday, 30'th Jan 2025
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
04:01pm, Thursday, 30'th Jan 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
04:00pm, Thursday, 30'th Jan 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor can
